You are here: Home » Current Affairs » News » National
Business Standard

This AI-based algorithm will help identify cancer-causing cell alterations

Researchers at the Indian Institute of Technology (IIT), Madras have developed an artificial intelligence-based mathematical model to identify cancer-causing alterations in cells.

cancer | IIT Madras

Press Trust of India  |  New Delhi 

Why aren't cancer drugs better? The targets might be wrong

Researchers at the Indian Institute of Technology (IIT), Madras have developed an artificial intelligence-based mathematical model to identify cancer-causing alterations in cells.

The algorithm uses a relatively unexplored technique of leveraging DNA composition to pinpoint genetic alterations responsible for progression. The results have been recently published in the reputed peer-reviewed International Journal of

According to the team, is caused due to the uncontrolled growth of cells driven mainly by genetic alterations. In recent years, high-throughput DNA sequencing has revolutionised the area of cancer research by enabling the measurement of these alterations.

However, due to the complexity and size of these sequencing datasets, pinpointing the exact changes from the genomes of cancer patients is notoriously difficult.

"One of the major challenges faced by cancer researchers involves the differentiation between the relatively small number of 'driver' mutations that enable the cancer cells to grow and the large number of 'passenger' mutations that do not have any effect on the progression of the disease," said B Ravindran, head of Robert Bosch Centre for Data Science and AI (RBCDSAI),

The model will help in identifying the most appropriate treatment strategy for a patient through an approach known as "precision oncology" and "tailoring treatments" not only to a specific illness but also to a person's genetic make-up is challenging and requires extensive cataloguing of the 'driver' variants of interest.

The researchers hope that the 'driver' mutations predicted through their mathematical model will ultimately help discover potentially novel drug targets and advance the notion of prescribing the "right drug to the right person at the right time".

"In most of the previously published techniques, researchers typically analysed DNA sequences from large groups of cancer patients, comparing sequences from cancer as well as normal cells, and determined whether a particular mutation occurred more often in cancer cells than random. However, this 'frequentist' approach often missed out on relatively rare 'driver' mutations," said Karthik Raman, associate professor,

"Detecting 'driver' mutations, particularly rare ones, is an exceptionally difficult task, and the development of such methods can ultimately accelerate early diagnoses and the development of personalised therapies."

Developing an easy-to-use web interface that will enable cancer researchers to get predictions on their preferred set of variants, studying the context of these mutations, and how they impact the evolution of cancer are among the next steps the team will be working on.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, July 12 2021. 19:27 IST